| Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $0.4373 per share, which is equal to the closing price of Tenaya's common stock on May 15, 2025. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date. |
globenewswire.com |
2025-05-16 01:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting |
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease |
globenewswire.com |
2025-05-13 12:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 |
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene |
globenewswire.com |
2025-04-24 18:07:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting |
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced that interim data from the first three patients enrolled in the company's MyPEAK-1 Phase 1b/2 clinical trial of TN-201 were highlighted in a Late-Breaker presentation at the 2025 American College of Cardiology Scientific Sessions (ACC.25). |
globenewswire.com |
2025-03-31 14:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models |
SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications. |
globenewswire.com |
2025-03-24 10:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session |
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 |
globenewswire.com |
2025-03-19 10:30:00 |
Czytaj oryginał (ang.) |
| Insiders Are Loading Up on These 4 Biotech Stocks Now |
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so. |
247wallst.com |
2025-03-11 10:45:13 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy |
globenewswire.com |
2025-03-10 18:05:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Pricing of Public Offering |
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses. |
globenewswire.com |
2025-03-04 01:19:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Proposed Public Offering |
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2025-03-03 18:10:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Participate in Upcoming March Investor Conferences |
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine |
Funding will Support Ongoing RIDGE™ -1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy |
globenewswire.com |
2025-02-03 10:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones |
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025. |
globenewswire.com |
2025-01-13 11:16:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics price target lowered to $6 from $8 at Leerink |
Leerink lowered the firm's price target on Tenaya Therapeutics to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy following program updates in October. The firm notes that while evidence of expression was present, clinical benefit is yet to be determined. Updated Cohort 1 data are expected in the first half of 2025, while initial Cohort 2 and MyClimb natural history data are expected in 2025. |
https://thefly.com |
2024-12-17 16:03:10 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 |
Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET |
globenewswire.com |
2024-12-16 18:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy |
globenewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM |
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling |
globenewswire.com |
2024-10-17 20:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Participate in Upcoming Investment Conferences |
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows: |
globenewswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |
| 5 Penny Stocks With 250% Upside in 1 Year According to Wall Street |
Penny stocks represent an interesting investment opportunity. |
247wallst.com |
2024-07-30 12:49:02 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Research Leadership Updates |
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role |
globenewswire.com |
2024-06-27 21:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit |
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET. |
globenewswire.com |
2024-06-18 20:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update |
Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024 |
globenewswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting |
Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines |
globenewswire.com |
2024-05-02 21:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update |
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. |
globenewswire.com |
2024-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine |
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) |
globenewswire.com |
2024-03-18 10:30:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Participate in Upcoming March Investor Conferences |
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows: |
globenewswire.com |
2024-02-27 18:30:00 |
Czytaj oryginał (ang.) |
| Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? |
After reaching an important support level, Tenaya Therapeutics, Inc. (TNYA) could be a good stock pick from a technical perspective. TNYA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. |
zacks.com |
2024-02-26 12:56:14 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications |
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease |
globenewswire.com |
2024-02-26 10:30:00 |
Czytaj oryginał (ang.) |
| Insider Buying: Taking a Controlling Stake in a Struggling Retailer? |
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment. |
24/7 Wall Street |
2024-02-18 13:20:54 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-02-09 12:56:21 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics Announces Pricing of Underwritten Offering |
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares of its common stock at a purchase price of $4.499 per each pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. All of the securities are to be sold by Tenaya. The deal included participation from new and existing investors including The Column Group, RA Capital Management, Venrock Healthcare Capital Partners, Octagon Capital, funds and accounts managed by BlackRock, Armistice Capital, Integral Health Asset Management, PFM Health Sciences, LP, Soleus Capital, as well as two large investment management firms. Before deducting the underwriting discounts and commissions and offering expenses, Tenaya expects to receive total gross proceeds of approximately $50 million. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-02-08 10:00:00 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why |
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-01-26 15:01:03 |
Czytaj oryginał (ang.) |
| Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT. |
globenewswire.com |
2024-01-03 10:30:00 |
Czytaj oryginał (ang.) |